Revance Therapeutics Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Revance Therapeutics Inc 's ROA in the third quarter of 2024?
Revance Therapeutics Inc recorded a cumulative net loss of $-2 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -0.38%.

However, within the Healthcare sector 194 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2024 from 899 to 2685.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter
Y / Y Total Assets Change	-13.05 %	-20.96 %	-13.82 %	-21.83 %	-28.99 %
Y / Y Net Income Change	-	-	-	1.06 %	-
Net Income (TTM) in million	-2	36	6	0	-2
Return On Assets (TTM)	-0.38 %	8.08 %	1.33 %	-0.06 %	-0.31 %
RVNC's Total Ranking	# 2685	# 899	# 2139	# 3091	# 2829
Total Assets (TTM) in million	417	447	441	425	479
Seq. Total Assets Change	-6.74 %	1.38 %	3.84 %	-11.44 %	-15.22 %
Seq. Net Income Change	-	-	-	-	-

RVNC's 5 Years Annual ROA >> Back to RVNC Management Effectiveness >> Compare RVNC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 61
Sector	# 195
Overall	# 2640

Return On Assets Statistics
High	Average	Low
7.19 %	-41.6 %	-92.62 %
(Jun 30 2024)		(Dec 31 2021)

Financial Statements
Revance Therapeutics Inc 's Assets	$ 417 million	RVNC's Balance sheet
Revance Therapeutics Inc 's Income	$ -38 million	Quarterly RVNC's Income Statement
RVNC's Income by Division		See RVNC's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	-21.24 %	11.04 %	-29.45 %	103.73 %	50.34 %
Total Assets in million	428	543	489	693	340
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	0	-1	-563	3	-319
Annual Return On Assets	-0.07 %	-0.13 %	-115.03 %	0.38 %	-93.7 %

RVNC's 5 Years Annual ROA >> Back to RVNC Management Effectiveness >> Compare RVNC ROA to its Competitors

More Return On Assets Ratios
RVNC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RVNC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RVNC's Competitors
Subscribers only: Roa for Revance Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for RVNC's Customers

You may also want to know
RVNC's Roi	RVNC's Inventory Turnover Ratio	RVNC's Growth Rates	RVNC's Dividend Comparisons
	RVNC's Profitability Ratios	RVNC's Asset Turnover Ratio	RVNC's Dividend Growth
RVNC's Roe	RVNC's Valuation Ratios	RVNC's Financial Strength Ratios	RVNC's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:00:27+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.